A Dose Escalation Study of OMP-59R5 in Subjects With Solid Tumors
NCT01277146
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
42
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumors
Interventions
DRUG:
OMP-59R5
Sponsor
OncoMed Pharmaceuticals, Inc.